SGLT-2 Inhibitors for Reduction of Hypoglycaemia After Bariatric Surgery

ChangeBridge: EPO Bulletin - Therapeutics (A61P)

Published March 25th, 2026

Detected April 1st, 2026

Summary

The European Patent Office published patent application EP3908274A1 by Universitätsspital Basel for the use of SGLT-2 inhibitors to reduce hypoglycaemia in patients who have undergone bariatric surgery. The application covers pharmaceutical compositions containing SGLT-2 inhibitors for this specific medical indication. The patent is designated across 34 European states including major markets.

View original document View source feed page

What changed

EPO published patent application EP3908274A1 (filed March 25, 2026) by Universitätsspital Basel claiming SGLT-2 inhibitors for reducing hypoglycaemia after bariatric surgery. The application covers A61K 31/7048 compounds (A61P 3/08 classification) and names inventor DONATH, Marc. Designated states include AT, BE, DE, ES, FR, GB, IT, NL, and 26 other European jurisdictions.\n\nPatent publications do not create compliance obligations for third parties. Pharmaceutical companies developing SGLT-2 therapies may wish to review this application for freedom-to-operate considerations when expanding indications to post-bariatric surgery patients. No action is required as this is an unexamined application at the publication stage.

Source document (simplified)

← EPO Patent Bulletin

SGLT-2 INHIBITORS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY

Publication EP3908274A1 Kind: A1 Mar 25, 2026

Applicants

Universitätsspital Basel

Inventors

DONATH, Marc

IPC Classifications

A61K 31/7048 20060101AFI20250117BHEP A61P 3/08 20060101ALI20250117BHEP A61K 38/17 20060101ALI20250117BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →